Note 5 - Net Income (Loss) Per Share

9 Months Ended

Mar. 31, 2016

Notes to Financial Statements

Earnings Per Share [Text Block]

(5)   Net Income (Loss) per share

Basic and diluted net income (loss) income per share has been computed based on net loss and the weighted-average number of common shares outstanding during the applicable period. For diluted net income (loss) per share, common stock equivalents (shares of common stock issuable upon the exercise of stock options and unvested restricted stock units) are excluded from the calculation as their inclusion would be anti-dilutive. The Company has excluded all anti-dilutive share-based awards to purchase common stock in periods indicating a loss, as their effect is anti-dilutive.

Aviragen Therapeutics, Inc.

 

Notes to the Condensed Consolidated Financial Statements (unaudited)

(for the quarterly period ended March 31, 2016)

The following tables set forth the computation of historical basic and diluted net income (loss) per share.

	Three Months Ended March 31 ,
	201 6			201 5
Net income (loss) (in millions)	$	(5.2	)	$	1.2
Weighted-average shares outstanding		38,640,254			35,105,978
Dilutive effect of restricted stock and stock options		-			37,200
Shares used to compute diluted earnings per share		38,640,254			35,143,178
Basic net income (loss) per share	$	(0.14	)	$	0.03
Diluted net income (loss) income per share	$	(0.14	)	$	0.03
Number of anti-dilutive share-based awards excluded from computation		4,639,959			3,333,392

	Nine Months Ended March 31 ,
	201 6			2015
Net income (loss) (in millions)	$	(18.4	)	$	0.8
Weighted-average shares outstanding		38,633,786			35,102,609
Dilutive effect of restricted stock and stock options		-			24,404
Shares used to compute diluted earnings per share		38,633,786			35,127,013
Basic net income (loss) per share	$	(0.48	)	$	0.02
Diluted net income (loss) per share	$	(0.48	)	$	0.02
Number of anti-dilutive share-based awards excluded from computation		4,639,959			3,346,188